Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. on August 19, 2024. The report details a corporate action involving a reverse stock split of the Company's common stock, effective August 20, 2024. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol "CVKD."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure adjustments rather than operational financial performance.
Material Changes
- Reverse Stock Split: The Company executed a 1-for-15 reverse stock split.
- Share Count Reduction: Outstanding shares were reduced from approximately 16 million to approximately 1.1 million.
- Ownership: Shareholder ownership percentages remain unchanged, excluding adjustments for fractional shares.
- Equity Adjustments: Proportional adjustments were made to the number of shares issuable upon exercise or conversion of outstanding equity awards and warrants, as well as their applicable exercise prices.
- Fractional Shares: No fractional shares were issued; holders received cash payments based on the average closing sales price for the ten days preceding the effective time.
Outlook, Risks, and Management Commentary
Management stated that the primary objective of the reverse stock split is to bring the Company into compliance with the Nasdaq Capital Market's minimum bid price requirement, which mandates a price of at least $1.00 per share. The Company also intends to make the bid price more attractive to investors. The new CUSIP number for the common stock following the split is 127636 207.
Key Facts for Investor Verification
- Verify the post-split share price on August 20, 2024, to confirm compliance with the $1.00 minimum bid price requirement.
- Confirm the updated CUSIP number (127636 207) for trading and settlement purposes.
- Review the adjusted exercise prices and share counts for any outstanding warrants or equity awards held.
- Check for any cash payments received in lieu of fractional shares if applicable.